Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.67 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.57 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | CDK4 | P11802 | 2/20 | 0.56 |
| ▸ | CCND1 | P24385 | 2/20 | 0.56 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30719652 | 1.00 | ATM (0.67) | ATMNPSR1PDE4APDE4BPDE4C | |
| SCHEMBL1934226 | 0.86 | PDE4A (0.52) | ATMNPSR1PDE4APDE4BPDE4C | |
| SCHEMBL4124300 | 0.86 | ENPP1 (0.66) | ATMNPSR1PDE4APDE4BPDE4C | |
| SCHEMBL4841775 | 0.84 | GSK3A (0.62) | ATMNPSR1PDE4APDE4BPDE4C | |
| SCHEMBL4843618 | 0.83 | GSK3A (0.65) | ATMNPSR1PDE4APDE4BPDE4C | |
| SCHEMBL6591973 | 0.83 | GSK3A (0.65) | ATMNPSR1PDE4APDE4BPDE4C | |
| SCHEMBL2887372 | 0.83 | KDM4E (0.54) | ATMNPSR1PDE4APDE4BPDE4C | |
| SCHEMBL2885503 | 0.82 | CCNE2 (0.56) | ATMNPSR1PDE4APDE4BPDE4C | |
| SCHEMBL4837386 | 0.82 | ENPP1 (0.56) | PDE4APDE4BPDE4CPDE4DMAPK1 | |
| SCHEMBL4837888 | 0.82 | GSK3A (0.53) | PDE4APDE4BPDE4CPDE4DMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117659025-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-03-08 | — | — | CN | disclosed |
| CN-117586108-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-02-23 | — | — | CN | disclosed |
| CN-117586191-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-02-23 | — | — | CN | disclosed |
| CN-111542515-B | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2023-12-05 | — | — | CN | disclosed |
| US-20230132035-A1 | Toll-Like Receptor 8 (TLR8)-Specific Antagonists and Methods of Making and Uses Thereof | UNIV COLORADO REGENTS (US) | 2023-04-27 | — | — | US | disclosed |
| US-11466010-B2 | Toll-like receptor 8 (TLR8) specific antagonists and methods of making and uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-10-11 | — | — | US | disclosed |
| US-20210179621-A1 | Toll-Like Receptor 8 (TLR8) Specific Antagonists and Methods of Making and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2021-06-17 | — | — | US | disclosed |
| CN-111542515-A | TOLL-like receptor 8(TLR8) specific antagonist and preparation method and application thereof | 科罗拉多州立大学董事会法人团体 | 2020-08-14 | — | — | CN | disclosed |
| US-8629143-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8124584-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | MSD K.K. (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1590442-A4 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2007-07-18 | — | — | EP | disclosed |
| US-7220858-B2 | Synthesis of hydrazine and chlorinated derivatives of bicyclic pyridazines | BARBEAU PHARMA, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1719756-A1 | NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1590442-A3 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-03 | — | — | EP | disclosed |
| EP-1590442-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-20050137397-A1 | Synthesis of hydrazine derivatives of pyridazine | BIONICHE TEORANTA | 2005-06-23 | — | — | US | disclosed |
| US-20040180815-A1 | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors | NAKAJIMA SUANNE (US) | 2004-09-16 | — | — | US | disclosed |
| WO-2004072243-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, TMPRSS4 | ATM 4056/4885NPSR1 2012/4885PDE4A 876/4885 |
| US-20040180815-A1 | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, TMPRSS4 | ATM 4253/4885NPSR1 2424/4885PDE4A 667/4885 |
| US-20230132035-A1 | Toll-Like Receptor 8 (TLR8)-Specific Antagonists and Methods of Making and Uses Thereof | TLR8, TLR3, TLR9 | ATM 3143/4885NPSR1 760/4885PDE4A 843/4885 |
| US-20050137397-A1 | Synthesis of hydrazine derivatives of pyridazine | DHPS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HPD | ATM 3966/4885NPSR1 1845/4885PDE4A 1711/4885 |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | HRH3, HRH2, HRH4 | ATM 3753/4885NPSR1 23/4885PDE4A 4780/4885 |
| US-20210179621-A1 | Toll-Like Receptor 8 (TLR8) Specific Antagonists and Methods of Making and Uses Thereof | TLR8, TLR3, TLR9 | ATM 3168/4885NPSR1 783/4885PDE4A 905/4885 |
| US-11466010-B2 | Toll-like receptor 8 (TLR8) specific antagonists and methods of making and uses thereof | TLR8, TLR3, TLR9 | ATM 3168/4885NPSR1 783/4885PDE4A 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.